Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company

Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease

Fineline Cube Apr 24, 2024

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released...

Company Drug

European Commission Approves Pfizer’s Antibiotic Emblaveo for Multiple Indications

Fineline Cube Apr 24, 2024

The European Commission (EC) has granted approval for Pfizer’s (NYSE: PFE) antibiotic Emblaveo (aztreonam +...

Company Drug

BeiGene’s Tislelizumab Secures EC Approval for Three NSCLC Indications

Fineline Cube Apr 24, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the European Committee (EC) has...

Company Drug

Shanghai Henlius Biotech Achieves First Patient Dosing in Phase I Trial for Fibrosis Treatment HLX6018

Fineline Cube Apr 24, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced the...

Policy / Regulatory

China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value

Fineline Cube Apr 24, 2024

The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in...

Company Drug

China Medical System Holdings’ Desidustat NDA Accepted for Review by China’s NMPA

Fineline Cube Apr 24, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that the National Medical Products Administration...

Company Drug

Akeso Biopharma Submits sNDA for Cadonilimab in Cervical Cancer to China’s CDE

Fineline Cube Apr 24, 2024

China-based Akeso Biopharma (HKG: 9926) has announced the submission of a supplementary New Drug Application...

Company Drug

Huadong Medicine’s HDM1005 Receives US FDA Clinical Trial Approval for Weight Management

Fineline Cube Apr 23, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clinical trial...

Company Drug

Sandoz’s Partner Samsung Bioepis Scores EC Approval for Stelara Biosimilar Pyzchiva

Fineline Cube Apr 23, 2024

Switzerland-headquartered Sandoz (SWX: SDZ) has announced that the European Commission (EC) has granted approval for...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Go-Ahead for Camrelizumab Combination Therapy Study in Pancreatic Cancer

Fineline Cube Apr 23, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Zhejiang Dian Diagnostics Partners with Henan Institute to Open Neuroimmunity Research Center

Fineline Cube Apr 23, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a medical diagnostics company based in China, has...

Company Drug

CanSino Biologics Receives NMPA Approval for Haemophilus influenzae type B (Hib) Conjugate Vaccine Clinical Trial

Fineline Cube Apr 23, 2024

China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced that it has received clinical trial...

Company Drug

CANbridge Pharmaceuticals’ CAN008 Fails to Meet Phase II Endpoints in Glioblastoma Multiforme

Fineline Cube Apr 23, 2024

CANbridge Pharmaceuticals (HKG: 1228) has announced that its Phase II clinical study for CAN008 (asunercept)...

Company Deals R&D

Shenzhen Wingor Biotechnology Partners with Guangzhou Institute of Respiratory Health for MSC Exos Research

Fineline Cube Apr 23, 2024

Shenzhen Wingor Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a scientific research...

Company Deals

Kingmed Diagnostics Partners with GenStar Biosolutions to Develop Auto-Antibody Immunofluorescence AI Software

Fineline Cube Apr 23, 2024

Kingmed Diagnostics, a leading independent medical laboratory based in Guangdong, has entered into a strategic...

Company Drug

GenScript’s Subsidiary Legend Biotech Expands EU Approval for CAR-T Therapy Carvykti

Fineline Cube Apr 23, 2024

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company Drug

Ipsen’s Somatuline Receives First Prescription in China for GEP-NETs Treatment

Fineline Cube Apr 23, 2024

French biopharmaceutical company Ipsen (EPA: IPN; OTCMKTS: IPSEY) has announced that the first prescription of...

Company

Chongqing Zhifei Biological Reports 38.3% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 23, 2024

Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a biopharmaceutical company based in China, has released...

Company Deals

Genrix Biopharmaceutical Partners with China Resource Medicine for Expanded Market Coverage

Fineline Cube Apr 23, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has entered into a...

Company Deals

Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture

Fineline Cube Apr 23, 2024

Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot...

Posts pagination

1 … 378 379 380 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.